The amido-tetrahydro acridine derivatives HBX19818 and HBX28258 (Figure 8) act as USP7 covalent inhibitors, resulting in HBX19818 being effective against both CRC and chronic lymphoid leukemia (CLL), whereas HBX28258 is active only against CRC [15]. This evidence concerns the gene USP7 and colorectal carcinoma.